Julian Adams
Chairman at ELICIO THERAPEUTICS, INC.
Net worth: 24 806 $ as of 2024-04-29
Julian Adams active positions
| Companies | Position | Start | End |
|---|---|---|---|
| GAMIDA CELL LTD. | Director/Board Member | 2018-09-17 | - |
| Independent Dir/Board Member | 2018-09-17 | - | |
| Chief Executive Officer | 2017-11-19 | 2022-09-18 | |
| Chairman | 2016-11-20 | 2018-09-17 | |
| ELICIO THERAPEUTICS, INC. | Chairman | 2016-12-31 | - |
| Independent Dir/Board Member | 2016-12-31 | - | |
| Princess Margaret Cancer Foundation | Director/Board Member | 2014-10-31 | - |
Career history of Julian Adams
Former positions of Julian Adams
| Companies | Position | Start | End |
|---|---|---|---|
Elicio Therapeutics, Inc. (Old)
 Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Chairman | 2016-12-31 | 2023-05-31 |
| NEON THERAPEUTICS, INC. | Director/Board Member | 2017-12-11 | 2018-08-27 |
| Independent Dir/Board Member | 2017-12-11 | 2018-08-27 | |
| PIERIS PHARMACEUTICALS, INC. | Director/Board Member | 2016-07-25 | 2018-07-23 |
| Independent Dir/Board Member | 2016-07-25 | 2018-07-23 | |
| CLAL BIOTECHNOLOGY INDUSTRIES LTD. | President | 2017-01-31 | 2017-10-31 |
| INFINITY PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2006-08-31 | 2017-01-05 |
| AILERON THERAPEUTICS, INC. | Director/Board Member | 2011-05-11 | 2012-12-31 |
| ░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ | - | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - | |
| ░░░░░ ░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░ ░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░ ░░░░░░░░ ░░░░░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░ ░░░░░░░░░░ ░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░░ ░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Training of Julian Adams
| McGill University | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Statistics
International
| United States | 18 |
| Israel | 4 |
| Canada | 3 |
Operational
| Director/Board Member | 9 |
| Corporate Officer/Principal | 4 |
| Independent Dir/Board Member | 4 |
Sectoral
| Health Technology | 15 |
| Finance | 5 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 7 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| AILERON THERAPEUTICS, INC. | Health Technology |
| CLAL BIOTECHNOLOGY INDUSTRIES LTD. | Finance |
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| GAMIDA CELL LTD. | Health Technology |
| PIERIS PHARMACEUTICALS, INC. | Health Technology |
| ELICIO THERAPEUTICS, INC. | Health Technology |
| Private companies | 13 |
|---|---|
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
LeukoSite, Inc.
 LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA. | Health Technology |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Health Technology |
ProScript, Inc.
 ProScript, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., ProScript, Inc. is a private company that develops anti-cancer treatments. The company is based in Cambridge, MA. The company was founded by Tom Maniatis. ProScript was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on July 20, 1999 for $3.35 million. | Health Technology |
Limulus Management Co. LLC
 Limulus Management Co. LLC Investment ManagersFinance Limulus Management Co. LLC is a venture capital firm founded by Lawrence Miller and Paul Howard in 1999. It is headquartered in Newton, Massachusetts. | Finance |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Health Technology |
Predix Pharmaceuticals Holdings, Inc.
 Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | Health Technology |
CureTech Ltd.
 CureTech Ltd. BiotechnologyHealth Technology CureTech Ltd. operates as a biotechnology company. It develops novel and immune modulating products for the treatment and control of cancer. The company was founded by Michael Schickler in 1995 and is headquartered in Yavne, Israel. | Health Technology |
Clal Biotechnology Industries Ltd. (Venture Capital)
 Clal Biotechnology Industries Ltd. (Venture Capital) Investment ManagersFinance Clal Biotechnology Industries Ltd. (Clal Biotechnology Industries) is a venture capital division of Clal Biotechnology Industries Ltd. founded in 1993. The firm is headquartered in Tel Aviv, Israel. | Finance |
| Infinity Discovery, Inc. | |
Warp Drive Bio, Inc.
 Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Warp Drive Bio, Inc. focused on proprietary genomic technology to discover drugs of natural origin. The firm deployed proprietary platforms Genome Mining and Small Molecule Assisted Receptor Targeting (SMART) to discover and develop novel molecules addressing new pharmacologic mechanisms. The company was founded by Gregory L. Verdine, George McDonald Church, and James A. Wells in 2012 and was headquartered in Cambridge, MA. | Commercial Services |
| Princess Margaret Cancer Foundation | Miscellaneous |
BioNTech US, Inc.
 BioNTech US, Inc. BiotechnologyHealth Technology BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Julian Adams
- Experience